MGluR2-positive allosteric modulators: Therapeutic potential for treating cocaine abuse

Neuropsychopharmacology

Volumn 35, Issue 10, 2010, Pages 2007-2008

  Barrett, James E ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; BIPHENYLINDANONE A; COCAINE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ALLOSTERISM; ALZHEIMER DISEASE; ANXIETY; BINDING SITE; COCAINE DEPENDENCE; DEPRESSION; DOSE RESPONSE; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDUSTRY; ELECTROSTIMULATION; HUMAN; NEUROLOGIC DISEASE; NOTE; PARKINSON DISEASE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; COCAINE-RELATED DISORDERS; EXCITATORY AMINO ACID AGONISTS; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 77955670662     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.93     Document Type: Note

References (8)

1. Galici R, Jones CK, Hemstapat K, Nong Y, Exhemendia NG, Williams LC et al (2006). Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic-and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318: 173-185.
2. Hiranita T, Soto PL, Tanda G, Katz JL (2010). Reinforcing effects of s-receptor agonists in rats trained to self-administer cocaine. J Pharmacol Exp Ther 332: 515-524.
3. Jin X, Semenova S, Yang L, Ardecky R, Sheffler DJ, Dahl R et al (2010). The mGlur2 positive allosteric modulator BINA decreases cocaine self-administration and cue-induced cocaine-seeking and counteracts cocaine-induced enhancement of brain reward function in rats. Neuropsychopharmacology 35: 2021-2036.
4. Johnson MP, Baez M, Jagdmann GE, Britton TC, Large TH, Callagaro DO et al (2003). Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-ethoxyphenoxy)phenyl)-N- (2,2,2-trifluor-oethylsulfonyl)pyrid-3-ylmethylamine. J Med Chem 46: 3189-3192.
5. Marino MJ, Conn PJ (2006). Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Curr Opin Pharmacol 6: 98-102.
6. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV et al (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13: 1102-1107.
7. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD (2005). Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4: 131-144.
8. Tanda G, Newman AH, Katz JL (2009). Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors. Adv Pharmacol 57: 253-289.